Luca Santarelli, VectivBio CEO

Lu­ca Santarel­li's Vec­tivBio buys out small Mass­a­chu­setts biotech, re­dou­bling fo­cus on meta­bol­ic dis­ease

Lu­ca Santarel­li moved quick­ly af­ter spin­ning out Vec­tivBio from Ther­a­chon, get­ting an IPO set­tled in less than two years. On Tues­day, he con­tin­ued charg­ing for­ward with a new buy­out that will see Vec­tivBio ex­pand its pipeline sig­nif­i­cant­ly over the next year and a half.

Vec­tivBio has ac­quired Comet Ther­a­peu­tics for an undis­closed eq­ui­ty and cash sum, the biotech an­nounced Tues­day, aim­ing to tar­get a swath of rare meta­bol­ic dis­eases. The goal is to hit the ground run­ning, Santarel­li told End­points News, with four new pro­grams ex­pect­ed to launch at once and plans to en­ter the clin­ic in 18 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.